{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:05:40Z","timestamp":1777608340418,"version":"3.51.4"},"reference-count":47,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1536\/ihj.17-365","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T22:13:06Z","timestamp":1510870386000},"page":"847-852","source":"Crossref","is-referenced-by-count":26,"title":["Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan"],"prefix":"10.1536","volume":"58","author":[{"given":"Satoshi","family":"Kodera","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arihiro","family":"Kiyosue","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Weinstein MC, Skinner JA. Comparative effectiveness and health care spending-implications for reform. N Engl J Med 2010; 362: 460-5.","DOI":"10.1056\/NEJMsb0911104"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009; 302: 1437-43.","DOI":"10.1001\/jama.2009.1409"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Brouwers MC, Kho ME, Browman GP, <i>et al<\/i>. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010; 182: E839-42. (Review).","DOI":"10.1503\/cmaj.090449"},{"key":"4","unstructured":"4. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. <i>Methods for the Economic Evaluation of Health Care Programmes<\/i>. 4th ed. Oxford, England: Oxford University Press; 2015."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sanders GD, Neumann PJ, Basu A, <i>et al<\/i>. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016; 316: 1093-103.","DOI":"10.1001\/jama.2016.12195"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Husereau D, Drummond M, Petrou S, <i>et al<\/i>. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health 2013; 16: e1-5.","DOI":"10.1016\/j.jval.2013.02.010"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Development of an Official Guideline for the Economic Evaluation of Drugs\/Medical Devices in Japan. Value Health 2017; 20: 372-8.","DOI":"10.1016\/j.jval.2016.08.726"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 2003; 56: 317-25. (Review).","DOI":"10.1016\/S0895-4356(02)00609-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Drummond M, Brixner D, Gold M, Kind P, McGuire A, Nord E. Toward a consensus on the QALY. Value Health 2009; 12: S31-5.","DOI":"10.1111\/j.1524-4733.2009.00522.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ryen L, Svensson M. The willingness to pay for a quality adjusted life year: a review of the empirical literature. Health Econ 2014. (in press).","DOI":"10.1002\/hec.3085"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bertram MY, Lauer JA, De Joncheere K, <i>et al<\/i>. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ 2016; 94: 925-30.","DOI":"10.2471\/BLT.15.164418"},{"key":"12","unstructured":"12. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010; 19: 422-37."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Persad G, Wertheimer A, Emanuel EJ. Principles for allocation of scarce medical interventions. Lancet 2009; 373: 423-31.","DOI":"10.1016\/S0140-6736(09)60137-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Schlander M. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no (t yet an) exemplar of a deliberative process. J Med Ethics 2008; 34: 534-9. (Review).","DOI":"10.1136\/jme.2007.021683"},{"key":"15","unstructured":"15. Economic and Social Research Institute, Cabinet Office, Government of Japan. International Collaboration Projects 2010\/2011: Studies on Labour, Tax, and Social Security through the Method of Microdata Analysis. Cost effevtiveness analyasis of dyslipidemia in japan. Accessed Aug. 4, 2017. Available at: http:\/\/www.esri.go.jp\/jp\/prj\/int_prj\/prj-si2010\/sem_ps.html"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 2015; 314: 142-50.","DOI":"10.1001\/jama.2015.6822"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kazi DS, Moran AE, Coxson PG, <i>et al<\/i>. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 2016; 316: 743-53.","DOI":"10.1001\/jama.2016.11004"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Annemans L, Wittrup-Jensen K, Bueno H. A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention. J Med Econ 2010; 13: 418-27. (Review).","DOI":"10.3111\/13696998.2010.499731"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Tsutani K, Igarashi A, Fujikawa K, <i>et al<\/i>. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan. Intern Med 2007; 46: 157-62.","DOI":"10.2169\/internalmedicine.46.1843"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Gaspoz JM, Coxson PG, Goldman PA, <i>et al<\/i>. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346: 1800-6.","DOI":"10.1056\/NEJM200206063462309"},{"key":"21","doi-asserted-by":"crossref","first-page":"E438","DOI":"10.9778\/cmajo.20150056","volume":"3","year":"2015","unstructured":"21. Abdel-Qadir H, Roifman I, Wijeysundera HC. Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model. CMAJ Open 2015; 3: E438-46.","journal-title":"CMAJ Open","ISSN":"https:\/\/id.crossref.org\/issn\/2291-0026","issn-type":"print"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Inoue T, Kobayashi M, Uetsuka Y, Uchiyama S. Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarction. Circ J 2006; 70: 453-8.","DOI":"10.1253\/circj.70.453"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Singh SM, Wijeysundera HC. Cost-effectiveness of novel oral anticoagulants for stroke prevention in non-valvular atrial fibrillation. Curr Cardiol Rep 2015; 17: 61. (Review).","DOI":"10.1007\/s11886-015-0618-4"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kamae I, Hashimoto Y, Koretsune Y, <i>et al<\/i>. Cost-effectiveness analysis of apixaban against warfarin for stroke prevention in patients with nonvalvular atrial fibrillation in Japan. Clin Ther 2015; 37: 2837-51.","DOI":"10.1016\/j.clinthera.2015.10.007"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Cowper PA, DeLong ER, Whellan DJ, Allen LaPointe NM, Califf RM. Economic effects of beta-blocker therapy in patients with heart failure. Am J Med 2004; 116: 104-11.","DOI":"10.1016\/j.amjmed.2003.07.016"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Stewart S, McMurray JJ, Hebborn A, Coats AJ, Packer M. Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom. Int J Cardiol 2005; 100: 143-9.","DOI":"10.1016\/j.ijcard.2004.12.003"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Inomata T, Izumi T, Kobayashi M. Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan. Circ J 2004; 68: 35-40.","DOI":"10.1253\/circj.68.35"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tsevat J, Duke D, Goldman L, <i>et al<\/i>. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995; 26: 914-9.","DOI":"10.1016\/0735-1097(95)00284-1"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Glick H, Cook J, Kinosian B, <i>et al<\/i>. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail 1995; 1: 371-80.","DOI":"10.1016\/S1071-9164(05)80006-5"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Schadlich PK, Huppertz E, Brecht JG. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance. Pharmacoeconomics 1998; 14: 653-69.","DOI":"10.2165\/00019053-199814060-00006"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2004; 148: 122-8.","DOI":"10.1016\/j.ahj.2003.12.040"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. McMurray JJ, Andersson FL, Stewart S, <i>et al<\/i>. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2006; 27: 1447-58.","DOI":"10.1093\/eurheartj\/ehl016"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Imamura T, Kinugawa K, Nitta D, Komuro I. Tolvaptan reduces long-term total medical expenses and length of stay in aquaporin-defined responders. Int Heart J 2016; 57: 593-9.","DOI":"10.1536\/ihj.16-007"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Chen YF, Jowett S, Barton P, <i>et al<\/i>. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess 2009; 13: 1-320. (Review).","DOI":"10.3310\/hta13490"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Igarashi A, Inoue S, Ishii T, Tsutani K, Watanabe H. Comparative effectiveness of oral medications for pulmonary arterial hypertension network meta-analysis. Int Heart J 2016; 57: 466-72. (Review).","DOI":"10.1536\/ihj.15-459"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Magnuson EA, Farkouh ME, Fuster V, <i>et al<\/i>. Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation 2013; 127: 820-31.","DOI":"10.1161\/CIRCULATIONAHA.112.147488"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Cohen DJ, Osnabrugge RL, Magnuson EA, <i>et al<\/i>. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 2014; 130: 1146-57.","DOI":"10.1161\/CIRCULATIONAHA.114.009985"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Ariyaratne TV, Yap CH, Ademi Z, <i>et al<\/i>. A systematic review of cost-effectiveness of percutaneous coronary intervention vs. surgery for the treatment of multivessel coronary artery disease in the drug-eluting stent era. Eur Heart J Qual Care and Clin Outcomes 2016; 2: 261-70.","DOI":"10.1093\/ehjqcco\/qcw007"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Griffin SC, Barber JA, Manca A, <i>et al<\/i>. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ 2007; 334: 624.","DOI":"10.1136\/bmj.39129.442164.55"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Takura T, Tachibana K, Isshiki T, <i>et al<\/i>. Preliminary report on a cost-utility analysis of revascularization by percutaneous coronary intervention for ischemic heart disease. Cardiovasc Interv Ther 2017; 32: 127-36.","DOI":"10.1007\/s12928-016-0401-5"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Sugimoto K, Kobayashi Y, Kuroda N, Komuro I. Cost analysis of sirolimus-eluting stents in the Japanese health insurance system. Int Heart J 2009; 50: 723-30.","DOI":"10.1536\/ihj.50.723"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Neyt M, Van Brabandt H, Devos C. The cost-utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluations. BMC Cardiovasc Disord 2013; 13: 78. (Review).","DOI":"10.1186\/1471-2261-13-78"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Kimura T, Igarashi A, Ikeda S, <i>et al<\/i>. A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS (2) score in Japan. J Cardiol 69: 89-97.","DOI":"10.1016\/j.jjcc.2016.01.008"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Colquitt JL, Mendes D, Clegg AJ, <i>et al<\/i>. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation. Health Technol Assess 2014; 18: 1-560. (Review).","DOI":"10.3310\/hta18560"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Cao C, Liou KP, Pathan FK, <i>et al<\/i>. Transcatheter aortic valve implantation versus surgical aortic valve replacement: meta-analysis of clinical outcomes and cost-effectiveness. Curr Pharm Des 2016; 22: 1965-77. (Review).","DOI":"10.2174\/1381612822666160219120713"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Sharples L, Buxton M, Caine N, <i>et al<\/i>. Evaluation of the ventricular assist device programme in the UK. Health Technol Assess 2006; 10: 1-119. (Review).","DOI":"10.3310\/hta10480"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Seco M, Zhao DF, Byrom MJ, <i>et al<\/i>. Long-term prognosis and cost-effectiveness of left ventricular assist device as bridge to transplantation: A systematic review. Int J Cardiol 2017; 235: 22-32.","DOI":"10.1016\/j.ijcard.2017.02.137"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/6\/58_17-365\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T07:54:22Z","timestamp":1570348462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/6\/58_17-365\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.17-365","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}